RVX.TO - Resverlogix Corp.

Toronto - Toronto Delayed Price. Currency in CAD
1.38
+0.11 (+8.66%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.27
Open1.31
Bid1.33 x 0
Ask1.38 x 0
Day's Range1.31 - 1.39
52 Week Range1.23 - 2.47
Volume30,371
Avg. Volume44,470
Market Cap244.007M
Beta2.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Who Are The Major Shareholders Of Resverlogix Corp (TSE:RVX)?
    Simply Wall St.2 months ago

    Who Are The Major Shareholders Of Resverlogix Corp (TSE:RVX)?

    In this article, I’m going to take a look at Resverlogix Corp’s (TSX:RVX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • How Does Resverlogix Corp (TSE:RVX) Affect Your Portfolio Returns?
    Simply Wall St.4 months ago

    How Does Resverlogix Corp (TSE:RVX) Affect Your Portfolio Returns?

    If you are looking to invest in Resverlogix Corp’s (TSX:RVX), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • How Should Investors React To Resverlogix Corp’s (TSX:RVX) CEO Pay?
    Simply Wall St.5 months ago

    How Should Investors React To Resverlogix Corp’s (TSX:RVX) CEO Pay?

    Don McCaffrey took the helm as Resverlogix Corp’s (TSX:RVX) CEO and grew market cap to CADCA$150.16M recently. Understanding how CEOs are incentivised to run and grow their company is anRead More...

  • Healthcare Stocks: Is Now The Time To Buy Resverlogix Corp (TSX:RVX)?
    Simply Wall St.6 months ago

    Healthcare Stocks: Is Now The Time To Buy Resverlogix Corp (TSX:RVX)?

    Resverlogix Corp (TSX:RVX), a CAD$198.30M small-cap, operates in the healthcare industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoing need for biotechRead More...

  • Zacks Small Cap Research8 months ago

    Resverlogix (RVX) Reports Fiscal Year 2017 Results

    By John Vandermosten, CFA TSX:RVX.V On July 25, Resverlogix Corp. (TSX:RVX.V) posted its financial statements and management discussion and analysis for fiscal year 2017, ending April 30, 2017.  The company ...

  • Newsfile9 months ago

    IIROC Trade Resumption - Resverlogix Corp.

    Toronto, Ontario--(Newsfile Corp. - July 25, 2017) - Trading resumes in: Company: Resverlogix Corp. TSX Symbol: RVX (all issues) ...

  • Newsfile9 months ago

    CORRECTION FROM SOURCE: IIROC Trade Halt - Resverlogix Corp.

    Toronto, Ontario--(Newsfile Corp. - July 25, 2017) - The following issues have been halted by IIROC: Company:  Resverlogix Corp. TSX Symbol: RVX (all issues) ...

  • Zacks Small Cap Research10 months ago

    RVX Price Decline Unjustified; Reiterate $6.50 Price Target and Highlight 3x Upside

    On June 20th, Resverlogix (RVX.TO) announced the close of its CAD$10 million in equity shares in its recent offering.  We anticipate the final details regarding net proceeds and shares issued will be available in the next week or two.  The CAD$10 million capital raise should be sufficient to provide the flexibility to negotiate a larger licensing or first right of refusal deal that will support clinical trials and operations until a new drug application can be submitted to the FDA, which we anticipate occurring in 2019.  Based on our conversations with management and the limited level of capital targeted in last week’s announcement, we anticipate that a larger deal is close at hand which will provide enough cash to fund the $2.0 to $2.5 million per month in anticipated cash burn. Cardiovascular disease is the number one killer in the world, with near 18 million people dying from this condition each year.  There are several high risk subgroups, including those with diabetes and kidney disease, which have shown promise using apabetalone therapy in clinical trials.  The United States, Europe and Latin America (RVX’s anticipated first markets) contain over six million individuals that could potentially benefit from the therapy, providing a substantial market for apabetalone if commercialized.  This ignores opportunities for apabetalone in other areas such as renal disease and where the drug’s epigenetic impact improves the regulation of pathways associated with disease.